CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Trial of PARP Inhibitor Niraparib for Men With High Risk Prostate Cancer and DNA Damage Response Defects

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04030559
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:24.846466+00:00
Published At: 2025-08-26T00:00:00+00:00
Record Updated At: 2025-08-26
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["ATM Gene Mutation", "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "BRIP1 Gene Mutation", "CDK12 Gene Mutation", "CHEK1 Gene Mutation", "CHEK2 Gene Mutation", "DNA Damage Response Gene Mutation", "DNA Repair Gene Mutation", "FANCA Gene Mutation", "FANCD2 Gene Mutation", "FANCL Gene Mutation", "GEN1 Gene Mutation", "NBN Gene Mutation", "Prostate Carcinoma", "RAD51 Gene Mutation", "RAD51C Gene Mutation"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-08-26"
protocolSection.identificationModule.nctId: "NCT04030559"
protocolSection.identificationModule.officialTitle: "Phase II Trial of PARP Inhibitor Niraparib for Men With High Risk Prostate Cancer and DNA Damage Response Defects"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.